FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars – Lexology (registration)
|
FDA Advisory Committee Recommends Approval of CAR–T Cell Therapy and Two New Biosimilars
Lexology (registration) The FDA's Oncologic Drug Advisory Committee (“ODAC”) held a public meeting on Wednesday, July 12, 2017, to consider Novartis' biologic license application (BLA 125646) for tisagenlecleucel (CTL019), an investigational chimeric antigen receptor T cell … |
